Result of General Meeting and Issue of Equity

RNS Number : 0886V

Redx Pharma plc

13 April 2016

 

13 April 2016

REDX PHARMA PLC

("Redx" or "the Company")

Result of General Meeting and Issue of Equity

Redx, the drug discovery and development company, is pleased to announce that, further to the announcement on 24 March, at the General Meeting held earlier today all resolutions proposed, as set out in the Notice of General Meeting circulated to shareholders, were duly passed.

As a result 285,714 and 22,105,518 ordinary shares of 1 pence each in the Company ("Ordinary Shares") will be admitted to trading on 14 and 15 April, respectively.

The new Ordinary Shares will rank pari passu with the existing Ordinary Shares in issue. Following Admission on 15 April, the Company's total issued share capital will comprise 93,552,638 Ordinary Shares. This number may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

For further information please contact:

Redx Pharma Plc	T: 0151 706 4747
Neil Murray, Chief Executive Company website: redxpharma.com
Cantor Fitzgerald Europe (Nomad & Broker)	T: 020 7894 7000
Phil Davies / Michael Reynolds
KTZ Communications	T: 020 3178 6378
Katie Tzouliadis/ Viktoria Langley/ Emma Pearson

About Redx Pharma Plc

 www.redxpharma.com

Redx is focused on the discovery and development of proprietary, small molecule therapeutics to address areas of high, unmet medical need, principally in cancer, infection and immunology, providing a pipeline of assets to larger and emerging companies. By improving the characteristics of existing drug classes to create highly differentiated, novel, best-in-class drugs, Redx has already established a portfolio of 14 proprietary (patent‑protected) drug programs. Six proofs of concept have been achieved across five programs, with relevance for respective therapies to treat MRSA, bone tumours, skin, brain, breast, pancreatic and blood cancers.

 

END

 

 

MSCIJMBTMBMBBIF